HBM Holdings investee firm completes A+++ financing round

HBM Holdings Limited announced that Shanghai NK Cell Technology Co., LTD ("NK Cell-Tech"), an investee company, has successfully completed an A+++ financing round. The round raised nearly RMB100 million from a group of investors. Proceeds from the financing will be used to advance clinical trials of NK Cell-Tech's core NK cell therapy product candidates and support further development of its product pipeline. HBM Holdings, via its subsidiary HBM Shanghai, holds a 10.90% equity interest in NK Cell-Tech. The investment reflects continued progress and strong investor confidence in NK Cell-Tech’s innovative immunotherapy platform. The company has obtained investigational new drug approvals from both the FDA and the National Medical Products Administration of the PRC in 2024. HBM Holdings advises shareholders and potential investors to exercise caution when dealing in the company’s securities.